ARTICLE | Deals
AstraZeneca to make COVID-19 vaccine with roots in Oxford’s CEPI-funded MERS project
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 30, 2020 10:35 PM UTC
Updated on May 1, 2020 at 11:59 PM UTC
When the first therapies and vaccines for COVID-19 are approved, it is likely that they will be the result of responses to prior viral outbreaks and pandemic preparedness programs. Products that will be hailed as overnight successes are actually the result of R&D stretching back years and in some cases decades.
Most of the COVID-19 vaccines in the clinic and those slated to start trials by early summer are modified versions of vaccines originally developed for other coronaviruses or were made possible by investments in pandemic and biodefense platforms...